- Process Development of the HCV NS5B Site D Inhibitor MK-8876
-
We describe the route development and multikilogram-scale synthesis of an HCV NS5B site D inhibitor, MK-8876. The key topics covered are (1) process improvement of the two main fragments; (2) optimization of the initially troublesome penultimate step, a key bis(boronic acid) (BBA)-based borylation; (3) process development of the final Suzuki-Miyaura coupling; and (4) control of the drug substance form. These efforts culminated in a 28 kg delivery of the desired active pharmaceutical ingredient.
- Williams, Michael J.,Chen, Qinghao,Codan, Lorenzo,Dermenjian, Renee K.,Dreher, Spencer,Gibson, Andrew W.,He, Xianliang,Jin, Yan,Keen, Stephen P.,Lee, Alfred Y.,Lieberman, David R.,Lin, Wei,Liu, Guiquan,McLaughlin, Mark,Reibarkh, Mikhail,Scott, Jeremy P.,Strickfuss, Sophie,Tan, Lushi,Varsolona, Richard J.,Wen, Feng
-
p. 1227 - 1238
(2016/07/23)
-
- INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE
-
Compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and /or viral production in a cell-based system. Wherein Z, R30, R40, R50 and R60 of compounds of formula (I) are herein defined as in the description.
- -
-
Page/Page column 40
(2011/10/03)
-
- INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE
-
Compounds of formula I that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infection and for inhibiting HCV viral replication and /or viral production in a cell-based system.
- -
-
Page/Page column 80-81
(2011/10/03)
-